Literature DB >> 7734316

Induction of apoptosis by anti-cancer drugs with disparate modes of action: kinetics of cell death and changes in c-myc expression.

A C Wood1, P Elvin, J A Hickman.   

Abstract

Incubation of CCRF CEM C7A human lymphoblastic leukaemia cells with etoposide (VP16) or N-methylformamide (NMF) induced apoptotic cell death. The kinetics of onset of apoptosis was determined and compared with that for dexamethasone-treated cells. The drugs induced 50% apoptosis at different rates: etoposide by approximately 18 h, NMF by 40 h and dexamethasone (DEX) by 52 h. In each case, the onset of apoptosis above 10% was preceded by a delay period. This was 8 h for etoposide, between 8 and 12 h for NMF and 36 h for dexamethasone. When cells were incubated for 36 h with dexamethasone and the drug washed out, addition of NMF induced apoptosis without any delay, suggesting that certain common biochemical events are required to prime the cells for apoptosis. However, cells treated for 8 h with NMF did not undergo immediate apoptosis on the addition of DEX. Analysis of the cellular content of the c-myc protein showed this to be undetectable by 2, 6 and 12 h after treatment with etoposide, NMF and DEX respectively. The rapid onset of NMF-induced cell death after a 36 h DEX pretreatment occurred 24 h after the loss of expression of c-Myc protein, suggesting that the expression of c-myc is not required for drug-induced cell death. In contrast to DEX-induced apoptosis, concomitant incubation of cells with NMF or etoposide and 200 nM of the protein synthesis inhibitor cycloheximide did not inhibit apoptotic cell death. The idea that drugs with different modes of action initiate conserved responses which engage a programmed cell death is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7734316      PMCID: PMC2033809          DOI: 10.1038/bjc.1995.181

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

Review 1.  DNA topoisomerase poisons as antitumor drugs.

Authors:  L F Liu
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

2.  Effects of N-methylformamide on the growth, cell cycle, and glutathione status of murine TLX5 lymphoma cells.

Authors:  C A Bill; A Gescher; J A Hickman
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

3.  Expression of c-myc changes during differentiation of mouse erythroleukaemia cells.

Authors:  H M Lachman; A I Skoultchi
Journal:  Nature       Date:  1984 Aug 16-22       Impact factor: 49.962

4.  Dexamethasone induces irreversible G1 arrest and death of a human lymphoid cell line.

Authors:  J M Harmon; M R Norman; B J Fowlkes; E B Thompson
Journal:  J Cell Physiol       Date:  1979-02       Impact factor: 6.384

Review 5.  Apoptosis and cancer chemotherapy.

Authors:  J A Hickman; C S Potten; A J Merritt; T C Fisher
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1994-08-30       Impact factor: 6.237

6.  Polar solvent-induced changes in membrane lipid lateral diffusion in human colon cancer cells.

Authors:  M D Dibner; K A Ireland; L A Koerner; D L Dexter
Journal:  Cancer Res       Date:  1985-10       Impact factor: 12.701

7.  Characterization of a glucocorticoid-sensitive human lymphoid cell line.

Authors:  M R Norman; E B Thompson
Journal:  Cancer Res       Date:  1977-10       Impact factor: 12.701

8.  Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product.

Authors:  G I Evan; G K Lewis; G Ramsay; J M Bishop
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

9.  Glucocorticoid effect on oncogene/growth gene expression in human T lymphoblastic leukemic cell line CCRF-CEM. Specific c-myc mRNA suppression by dexamethasone.

Authors:  Y S Yuh; E B Thompson
Journal:  J Biol Chem       Date:  1989-06-25       Impact factor: 5.157

Review 10.  Drug-target interactions: only the first step in the commitment to a programmed cell death?

Authors:  C Dive; J A Hickman
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

View more
  8 in total

1.  Splenic micronodular T-cell/histiocyte-rich large B-cell lymphoma: effect of prior corticosteroid therapy.

Authors:  Elena Kan; Itai Levy; Daniel Benharroch
Journal:  Virchows Arch       Date:  2009-09-09       Impact factor: 4.064

Review 2.  [Significance of apoptotic processes in radiotherapy. II].

Authors:  M Abend; D van Beuningen
Journal:  Strahlenther Onkol       Date:  1998-04       Impact factor: 3.621

Review 3.  Apoptosis: clinical relevance and pharmacological manipulation.

Authors:  U Thatte; S Dahanukar
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

Review 4.  Splenic Micronodular T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: The Corticosteroid Pretreatment Hypothesis.

Authors:  Benzion Samueli; Karen Nalbandyan; Daniel Benharroch; Itai Levi
Journal:  Acta Haematol       Date:  2021-11-09       Impact factor: 3.068

5.  Enhancement of antitumor activity of the oxazaphosphorine cytostatic SUM-IAP by N-methylformamide.

Authors:  G Voelcker
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-03       Impact factor: 4.553

6.  Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis.

Authors:  G J Griffiths; L Dubrez; C P Morgan; N A Jones; J Whitehouse; B M Corfe; C Dive; J A Hickman
Journal:  J Cell Biol       Date:  1999-03-08       Impact factor: 10.539

7.  Piceatannol, a Natural Analog of Resveratrol, Exerts Anti-angiogenic Efficiencies by Blockage of Vascular Endothelial Growth Factor Binding to Its Receptor.

Authors:  Wei-Hui Hu; Diana Kun Dai; Brody Zhong-Yu Zheng; Ran Duan; Tina Ting-Xia Dong; Qi-Wei Qin; Karl Wah-Keung Tsim
Journal:  Molecules       Date:  2020-08-19       Impact factor: 4.411

8.  Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.

Authors:  C F O'Neill; M G Ormerod; D Robertson; J C Titley; Y Cumber-Walsweer; L R Kelland
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.